Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.
Optune® Novocure™

Recurrent GBM efficacy

Optune monotherapy delivered comparable efficacy vs chemotherapy*

OS in EF-11, the pivotal phase 3 trial1

*Therapy options were the physican's best choice for chemotherapy, including bevacizumab, which were defined given historical assessment of effective recurrent GBM therapies. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.

Twice as many patients responded to Optune vs physician’s choice of chemotherapy3

Complete Response 3 (3) 0
Partial Response 11 (9) 7 (6)
Median Time to Response,
months (95% CI)
8.4 (6.9-9.9) 5.8 (3.6-8.0)
Median Response Duration,
months (95% CI)
7.3 (0.0-16.6) 5.6 (3.8-7.5)

OS correlated with treatment compliance in a subgroup analysis of patients treated with Optune2

Subgroup analysis of patients treated with Optune

  • OS was significantly higher in patients who received Optune for ≥18 hours per day (n=92) vs those who received therapy for <18 hours per day (n=28), 7.7 months vs 4.5 months, respectively (P=0.0042)2

  • Median compliance was 86% (range 41%-98%) of the time in each treatment month, translating into a mean use of 20.6 hours per day1

CI, confidence interval; GBM, glioblastoma; HR, hazard ratio; ITT, intent to treat; MRI, magnetic resonance imaging; OS, overall survival; PFS, progression-free survival; PFS6, progression-free survival at 6 months; QoL, quality of life.

References: 1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2­1­9­2­-­2­2­0­2. 2. Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators. Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy. Semin Oncol. 2014;41(suppl 6):S25-S34. 3. Wong ET, Lok E, Swanson KD, et al. Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. Cancer Med. 2014;3(3):5­9­2­-­6­0­2.

Results published in European Journal of Cancer

Access the article now.

View the results

A growing network

Search the treatment centers prescribing Optune.

View map


*The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial for which the IFU is based used an eligibility criteria of KPS ≥70.
The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information


Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

The most common (10%) adverse events seen with Optune monotherapy were medical device site reaction and headache.

The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).